Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study

Print
| Source: Anthera Pharmaceuticals, Inc.

HAYWARD, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs, today announced that additional data from its Phase 2b PEARL-SC study will be presented in a poster at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Rome, Italy.

As part of a guided poster tour on June 6th, 2015, Dr. Michelle Petri, Director of the Hopkins Lupus Center at Johns Hopkins University, will present breaking data on the impact of treatment with blisibimod on patient-reported fatigue and improvement in disease biomarkers.

"Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus"

Treatment with blisibimod was associated with statistically significant and clinically meaningful improvements in patient-reported fatigue, as measured by the FACIT-fatigue scale, over a similar time course as the SRI and SLE biomarker response rates.  These effects were most evident at the highest dose of blisibimod (200mg QW). The FACIT-fatigue scale is a measure of health-related quality of life with a specific focus on fatigue, tiredness and weakness. For more information on the CHABLIS-SC1 trial, please visit https://clinicaltrials.gov/ct2/show/NCT01395745?term=chablis&rank=1.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-Q for the year ended March 31, 2015. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

Dennis Lutz of Anthera Pharmaceuticals, Inc.,
dlutz@anthera.com or 510.856.5598